Adenosine A₁ modulators: a patent update (2008 to present)

Bibliography

• Giorgi I, Nieri P. Therapeutic potential of A1 adenosine receptor ligands: a survey of recent patent literature. Expert Opin Ther Pat 2008;18(7):1-15
   Google Scholar
• Boison D. Adenosine as a neuromodulator in neurological diseases. Curr Opin Pharmacol 2008;8(1):2-7
   PubMed Web of Science ®Google Scholar
• Schenone S, Brulo C, Musumeci F, et al. A1 receptors ligands: past, present and future trends. Curr Top Med Chem 2010;10:878-901
   PubMedGoogle Scholar
• Kalla R, Zablocki J. Recent advances in Adenosine Receptor (AR) ligands in pulmonary diseases. Ann Rep Med Chem 2009;44:265-77
   Google Scholar
• Ponnoth DS, Nadeem A, Tilley S, Mustafa SJ. Involvement of A1 adenosine receptors in altered vascular responses and inflammation in an allergic mouse model of asthma. Am J Physiol Heart Circ Physiol 2010;299:H81-7
   PubMed Web of Science ®Google Scholar
• Vallon V, Mühlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev 2006;86(3):901-40
   PubMed Web of Science ®Google Scholar
• Vannucci SJ, Klim CM, Martin LF, LaNoue KF. A1-adenosine receptor-mediated inhibition of adipocyte adenylate cyclase and lipolysis in Zucker rats. Am J Physiol Endocrinol Metab 1989;257:E871-8
   Google Scholar
• Hocher B. Adenosine A1 receptor antagonists in clinical research and development. Kidney Int 2010;78:438-44
   Web of Science ®Google Scholar
• Ponnoth D S, Mustafa SJ. Adenosine receptors and vascular inflammation. Biochim Biophys Acta 2011;1808:1429-34
   PubMedGoogle Scholar
• Wilson CN, Mustafa SJ. editors. Adenosine receptors in health and disease (Handbook of Experimental Pharmacology*). Springer-Verlag; Berlin Heidelgerg: 2009
   Google Scholar
• Lopes LV, Sebastião AM, Ribeiro JA. Adenosine and related drugs in brain diseases: present and future in clinical trials. Curr Top Med Chem 2011;11(8):1087-101
   PubMed Web of Science ®Google Scholar
• Muller C, Jacobson KA. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta 2011;1808:1290-308
   PubMed Web of Science ®Google Scholar
• Fredholm BB, IJzerman AP, Jacobson KA, et al. International union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev 2011;63:1-34
   PubMed Web of Science ®Google Scholar
• Fairhurst RA. Purine derivatives as adenosine al receptor ligands. WO2009050199; 2009
   Google Scholar
• Zablocki J, Elzein E, Organ MG, et al. Partial and full agonists of A1 adenosine receptors. WO2006026651; 2006
   Google Scholar
• Dhalla A, Elzein E. Adenosine derivatives as partial and full agonists of A1 adenosine receptors. WO2008077050; 2008
   Google Scholar
• Dhalla A, Elzein E, Prabha I, et al. Partial and full agonists of A1 adenosine receptors. US2009247557; 2009
   Google Scholar
• Jagtap P. Adenosine compounds and their use thereof. US2011245194; 2011
   Google Scholar
• Jacobson K, Tosh DK. Adenosine receptor agonists, partial agonists, and antagonists. US2012252823; 2012
   Google Scholar
• Rosentreter U, Kraemer T, Shimada M, et al. Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same. WO03053441; 2003
   Google Scholar
• Nell P, Huebsch W. Novel substituted bipyridine derivatives and their use as adenosine receptor ligands. WO2008028590; 2008
   Google Scholar
• Lerchen H-G, Krenz U, Keldenich J, et al. Dipeptoid prodrugs and the use thereof. WO2009015811; 2009
   Google Scholar
• Vakalopoulos A, Meibom D, Albrecht-Kuepper B, et al. Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof. WO2010086101; 2010
   Google Scholar
• Nell P, Huebsch W, Albrecht-Kuepper B, et al. Substituted aryloxazoles and the use thereof. WO2009015776; 2009
   Google Scholar
• Lerchen H-G, Vakalopoulos A, Meibom D, et al. Dipeptoid prodrugs and the use thereof. WO2010072314; 2010
   Google Scholar
• Klar J, Von Degenfeld G, Lerchen H-G, et al. Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension. WO2012028585; 2012
   Google Scholar
• Meibom D, Vakalopoulos A, Albrecht-Kuepper B, et al. Heteroaryl- substituted dicyanopyridines and their use. US2011207698; 2011
   Google Scholar
• Huebsch W, Nell P, Suessmeier F, et al. Cycloalkoxy-substituted 4-phenyl-3,5- dicyanopyridines and their use. US2011021487; 2011
   Google Scholar
• Huebsch W, Meibom D, Vakalopoulos A, et al. 2-Alkoxy-substituted dicyanopyridines and their use. US2011136871; 2011
   Google Scholar
• Nell P, Albrecht-Kuepper B, Huebsch W, et al. Use of Adenosine A1 and/or Dual A1/2ab agonists for production of medicaments for treating diseases. US2010048641; 2010
   Google Scholar
• Vakalopoulos A, Meibom D, Meibom D, et al. Substituted dicyanopyridines and use thereof. WO20120000945; 2012
   Google Scholar
• Hughes S. Rolofylline fails to PROTECT in acute heart failure. Barcelona: European Congress of cardiology. 2009. Available from: www.medscape.com/viewarticle/708267
   Google Scholar
• Gant T, Shahbaz MM. Xanthine modulators of adenosine A1 recepto. US2010075935; 2010
   Google Scholar
• Mugerditichian M, Dittrich H, Farmer B, et al. KW-3902 conjugates that do not cross the blood-brain barrier. WO2008024277; 2008
   Google Scholar
• Wilson C. A1. Adenosine receptor antagonists. WO2009086077; 2009
   Google Scholar
• Wilson C, Partridge JJ. A1 Adenosine receptor diagnostic probes. US2011282031; 2011
   Google Scholar
• NCT00744341. Safety and efficacy study to evaluate the effect of SLV320 on renal function in patients with worsening heart failure. Available from: http://clinicaltrials.gov/ct2/show/NCT00744341?term=SLV320&rank=1
   Google Scholar
• De Kanter R, Spaans P, Hesselink M, et al. Hydroxyphenyl-substituted pyrrolo[2,3d]pyrimidine derivatives, processes and intermediate products for their preparation and medicaments containing these compounds. WO2009153261; 2009
   Google Scholar
• Cole AG, Stauffer TM, Rokosz LL, et al. Synthesis of 2-amino-5-benzoyl-4-(2-furyl) thiazoles as adenosine A (2A) receptor Antagonists. Bioorg Med Chem Lett 2009;19:378-81
   PubMedGoogle Scholar
• Mogens L, Graven SA, Gitte M, et al. 2-Acylaminothiazole Derivatives. WO2006032273; 2006
   Google Scholar
• van Muijlwijk-Koezen JE, Timmerman H, Vollinga RC, et al. Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists. J Med Chem 2001;44:749-62
   PubMed Web of Science ®Google Scholar
• Gonzalez LL, Camacho GJA. New compounds as adenosine A1 receptor antagonists. WO2009044250; 2009
   Google Scholar
• Langmead CJ, Andrews S, Congreve M, et al. Identification of Novel Adenosine A2A Receptor by virtual screening. J Med Chem 2012;55:1904-9
   PubMed Web of Science ®Google Scholar
• Congreve MS, Andrews SP, Mason JS, et al. 1,2,4-Triazine-4-amine derivatives. WO2011095625; 2011
   Google Scholar
• Heintzelman GR, Bullington JL, Rupert KC. Arylindenopyridines and arylindenopyridines and their use as adenosine A2A receptor antagonist. WO2005042500; 2005
   Google Scholar
• Shook BC, Rassnick S, Hall D, et al. Methylene amine substituted arylindenopyrimidines as potent adenosine A2A/A1 antagonists. Bioorg Med Chem Lett 2010;20:2864-7
   PubMed Web of Science ®Google Scholar
• Shook BC, Rassnick S, Chakravarty D, et al. Optimization of arylindenopyrimidines as potent adenosine A2A/A1 antagonists. Bioorg Med Chem Lett 2010;20:2868-71
   PubMedGoogle Scholar
• Lim H-K, Chen J, Sensenhauser C, et al. Overcoming the genotoxicity of a pyrrolidine substituted arylindenopyrimidine as a potent dual adenosine A2A/A1 antagonist by minimizing bioactivation to an iminium ion reactive intermediate. Chem Res Toxicol 2011;24:1012-30
   PubMed Web of Science ®Google Scholar
• Jackson P, Shook B. Arylindenopyrimidines with reduced hERG channel binding. US2011312956; 2011
   Google Scholar
• Jackson P, Shook B. Arylindenopyrimidines for treating neurodegenerative and movement disorders while minimizing cardiac toxicity. WO2011159302; 2011
   Google Scholar
• Göblyös A, IJzerman AP. Allosteric modulation of adenosine receptors. Biochim Biophys Acta 2011;1808:1309-18
   PubMedGoogle Scholar
• Romagnoli R, Baraldi PG, Tabrizi MA, et al. Allosteric enhancers of A1 adenosine receptors: state of the art and new horizons for drug development. Curr Med Chem 2010;17(30):3488-502
   PubMed Web of Science ®Google Scholar
• NCT00809679 Analgesic efficacy and safety study of T-62 in subjects with postherpetic neuralgia. Available from: http://clinicaltrials.gov/ct2/show/NCT00809679?term=t-62&rank=1
   Google Scholar
• Laurence G, Moorman AR. Park A. Crystals of (2-amino-4,5,6,7-tetrahydrobenzo[b]thien-3-yl)(4-chlorophenyl)methanone. WO2009015004; 2009
   Google Scholar
• Baraldi PG, Moorman A, Romagnoli R. Allosteric enhancers of the A1 adenosine receptor. WO2009137782; 2009
   Google Scholar
• Baraldi PG, Moorman A, Romagnoli R. Allosteric enhancers of the A1 adenosine receptor. WO2008063984; 2008
   Google Scholar
• Baraldi PG, Moorman A, Romagnoli R. Allosteric enhancers of the A1 adenosine receptor. US2008119460; 2008
   Google Scholar
• Scammells P, Aurelio L, Christopoulos A. Adenosine receptor allosteric enhancers. WO2009049362; 2009
   Google Scholar
• NCT00713401 Safety study of tecadenoson to treat atrial fibrillation. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00713401?term=NCT00713401&rank=1
   Google Scholar
• NCT00568945 Study to investigate the effect of the A1 agonist capadenoson on ventricular HR in patients with persistent or permanent atrial fibrillation. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00568945?term=NCT00568945&rank=1
   Google Scholar
• McIntosh VJ, Lasley RD. Adenosine receptor-mediated cardioprotection: are all 4 subtypes required or redundant? J Cardiovasc Pharmacol Ther 2012;17(1):21-33
   PubMedGoogle Scholar
• Feldman A, Chan T. Compositions and methods for the treatment and prevention of cardiovascular diseases. WO2009076580; 2009
   Google Scholar
• Lee AJ, Goldberg I. Emerging drugs for ocular hypertension. Exp Opin Emerg Drugs 2011;16:137-61
   PubMed Web of Science ®Google Scholar
• Bagnis A, Papadia M, Scotto R, Traverso C. Current and emerging medical therapies in the treatment of glaucoma. Exp Opin Emerg Drugs 2011;16:293-307
   PubMed Web of Science ®Google Scholar
• Fogagnolo P, Rossetti L. Medical treatment of glaucoma: present and future. Exp Opin Invest Drugs 2011;20:947-59
   PubMed Web of Science ®Google Scholar
• Daines BS, Kent AR, McAleer MS, Crosson CE. Intraocular adenosine levels in normal and ocular-hypertensive patients. J Ocul Pharmacol Ther 2003;19:113-19
   Google Scholar
• Wu J, Li G, Luna C, et al. Endogenous production of extracellular adenosine by trabecular meshwork cells: potential role in outflow regulation. Invest Ophthalmol Vis Sci 2012;53:7142-8
   PubMed Web of Science ®Google Scholar
• Chen J, Runyan SA, Robinson MR. Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol 2011;5:667-77
   PubMedGoogle Scholar
• Crosson CE, Gray T. Modulation of intraocular pressure by adenosine agonists. J Ocul Pharmacol 1994;10:379-83
   PubMedGoogle Scholar
• Crosson CE. Adenosine receptor activation modulates intraocular pressure in rabbits. J Pharmacol Exp Ther 1995;273:320-6
   PubMed Web of Science ®Google Scholar
• Tian B, Gabelt BT, Crosson CE, Kaufman PL. Effects of adenosine agonists on intraocular pressure and aqueous humor dynamics in cynomolgus monkeys. Exp Eye Res 1997;64:979-89
   PubMed Web of Science ®Google Scholar
• Crosson CE, Sloan CF, Yates PW. Modulation of conventional outflow facility by the adenosine A1 agonist N6-cyclohexyladenosine. Invest Ophthalmol Vis Sci 2005;46:3795-9
   PubMed Web of Science ®Google Scholar
• NCT01123785 A dose-escalation study designed to evaluate the tolerability, safety, Pharmacokinetics (PK), and efficacy of chronic topical ocular application of INO-8875 in adults with ocular hypertension or primary open-angle glaucoma. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01123785?term=NCT01123785&rank=1
   Google Scholar
• Barman S, Baumgartner RA. Method of reducing intraocular pressure in humans. WO2010127210; 2010
   Google Scholar
• Kim NN, McVicar WK, McCauley TG. Combination compositions of adenosine a1 agonists and carbonic anhydrase inhibitors for reducing intraocular pressure. WO2011116290; 2011
   Google Scholar
• Kim NN, McVicar WK, McCauley TG. Combination compositions of adenosine A1 agonists and non-selective beta-adrenergic receptor blockers for reducing intraocular pressure. WO2011116292; 2011
   Google Scholar
• Kim NN, McVicar WK, McCauley TG, Baumgartner R. Combination, kit and method of reducing intraocular pressure. WO2011085361; 2011
   Google Scholar
• Jagtap P. Adenosine compounds and their use thereof. WO2011119919; 2010
   Google Scholar
• Kim N, Mcvicar W, Mccauley T, Jagtap P. Method of reducing intraocular pressure in humans using N6 -cyclopentyladenosine (CPA), CPA derivatives or prodrugs thereof. WO2011119969; 2011
   Google Scholar
• Zylka M. J. Pain relieving prospects for adenosine receptors and ectonucleotidases. Trends Mol Med 2011;17:188-96
   PubMed Web of Science ®Google Scholar
• NCT00809679 Analgesic efficacy and safety study of T-62 in subjects with postherpetic neuralgia. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00809679?term=NCT00809679&rank=1
   Google Scholar
• NCT00298636 Dose-response of adenosine for perioperative pain. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00298636?term=NCT00298636&rank=1
   Google Scholar
• NCT00376454 The Study of GW493838, an adenosine a1 agonist, in peripheral neuropathic pain. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00376454?term=NCT00376454&rank=1
   Google Scholar
• Beasley MW, Hause DP, Reynolds D. Pharmaceutical compositions for the treatment of pain. WO2008147939; 2008
   Google Scholar
• Eisenach JC. Combination therapy for the treatment of pain. WO2008051760; 2008
   Google Scholar
• Goldman N, Chen M, Fujita T, et al. Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture. Nat Neurosci 2010;13:883-8
   PubMed Web of Science ®Google Scholar
• Takano T, Chen X, Luo F, et al. Traditional acupuncture triggers a local increase in adenosine in human subjects. J Pain 2012;13:1215-23
   PubMed Web of Science ®Google Scholar
• Nedergaard M. Enhancing the therapeutic effect of acupuncture with adenosine. WO2011066412; 2011
   Google Scholar
• Dhalla AK, Chisholm JW. A1 adenosine receptor: role in diabetes and obesity. In: Wilson CN, Mustafa SJ, editors. Adenosine receptors in health and disease. Handbook of Experimental pharmacology. Springer-Verlag; Berlin Heidelberg: 2009. p. 271-95
   Google Scholar
• Faulhaber-Walter R, Jou W, Mizel D, et al. Impaired glucose tolerance in the absence of adenosine A1 receptor signaling. Diabetes 2011;60:2578-87
   PubMedGoogle Scholar
• Németh ZH, Bleich D, Csóka B, et al. Adenosine receptor activation ameliorates type 1 diabetes. FASEB J 2007;21:2379-88
   PubMed Web of Science ®Google Scholar
• Johnston-Cox H, Koupenova M, Yang D, et al. The A2b adenosine receptor modulates glucose homeostasis and obesity. PLoS One 2012;7(7):e40584
   Google Scholar
• Carman AJ, Mills JH, Krenz A, et al. Adenosine receptor signaling modulates permeability of the blood-brain barrier. J Neurosci 2011;31:13272-80
   PubMed Web of Science ®Google Scholar
• Hamilton C, Jorgensen ND. Compositions for treating cns disorders. WO2011057199; 2011
   Google Scholar
• Bynoe M. Use of adenosine receptor signaling to modulate permeability of blood-brain barrier. WO2012037457; 2012
   Google Scholar
• Ryzhov S, Solenkova NV, Goldstein AE, et al. Adenosine receptor-mediated adhesion of endothelial progenitors to cardiac microvascular endothelial cells. Circ res 2008;102:356-63
   PubMedGoogle Scholar
• Biaggioni I, Feoktistov I, Hatzopoulos A, et al. Use of adenosine receptor ligands to promote cell adhesion in cell-based therapies. US20090136460; 2009
   Google Scholar
• Vlajkovic SM, Housley GD, Thorne PR. Adenosine and the auditory system. Curr Neuropharmacol 2009;7:246-56
   PubMed Web of Science ®Google Scholar
• Wong AC, Guo CX, Gupta R, et al. Post exposure administration of A(1) adenosine receptor agonists attenuates noise-induced hearing loss. Hear Res 2010;260:81-8
   PubMed Web of Science ®Google Scholar
• Vlajkovic S, Thorne PR. The treatment of hearing loss. WO2010019057; 2010
   Google Scholar
• Howard D. Methods of treating heart failure and renal dysfunction in individuals with an adenosine A1 receptor antagonist. WO2008121893; 2008
   Google Scholar
• Wilson C. Methods and pharmaceutical compositions for preventing and treating renal impairment. WO2011094208; 2011
   Google Scholar
• Voors AA, Dittrich HC, Bassie BM, et al. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function. J Am Coll Cardiol 2011;57:1899-907
   PubMed Web of Science ®Google Scholar
• Marti C, Cole R, Kalogeropoulos A, et al. Medical therapy for acute decompensated heart failure: what recent clinical trials have taught us about diuretics and vasodilators. Curr Heart Fail Rep 2012;9(1):1-7
   PubMedGoogle Scholar
• Gomes CV, Kastera MP, Tomé AR, et al. Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochim Biophys Acta 2011;1808:1380-99
   PubMed Web of Science ®Google Scholar
• NCT00955526. Study of KW-6002 (Istradefylline) for the treatment of Parkinson's disease in patients taking Levodopa. Available from: http://www.clinicaltrials.gov/ct2/results?term=NCT00955526&Search=Search
   Google Scholar
• NCT01227265. Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3). Available from: http://www.clinicaltrials.gov/ct2/results?term=NCT01227265&Search=Search
   Google Scholar
• NCT01215227. An active-controlled extension study to P04938 and P07037 (P06153 AM3). Available from: http://www.clinicaltrials.gov/ct2/results?term=NCT01215227&Search=Search
   Google Scholar
• Vandenberg JI, Perry MD, Perrin MJ, et al. hERG K(+) channels: structure, function, and clinical significance. Physiol Rev 2012;92:1393-478
   PubMed Web of Science ®Google Scholar
• Shook BC, Rassnick S, Wallace N, et al. Design and characterization of optimized adenosine A2A/A1 receptor antagonists for the treatment of Parkinson's disease. J Med Chem 2012;55:1402-17
   PubMed Web of Science ®Google Scholar
• Vaughn BP, Robson SC, Burnstock G. Pathological roles of purinergic signaling in the liver. J Hepatol 2012;57(4):916-20
   PubMedGoogle Scholar
• Cronstein B, Peng Z. Methods and compositions for treating hepatic diseases. WO2009055021; 2009
   Google Scholar
• Hocher B, Heiden S, von Websky K, et al. Renal effects of the novel selective adenosine A1 receptor blocker SLV329 in experimental liver cirrhosis in rats. PLoS One 2011;6(3):e17891
   Google Scholar
• Wilson C. Methods and pharmaceutical compositions for treating sepsis. US2006276378; 2006
   Google Scholar
• Wilson C. Methods for preventing and treating tissue injury and sepsis associated with Yersinia pestis infection. US2009048155; 2009
   Google Scholar
• Wang Y. A1 Adenosine receptor antagonist-coated implantable medical device. WO2009114257; 2009
   Google Scholar
• Edwards JM, Alloosh MA, Long XL, et al. Adenosine A1 receptors in neointimal hyperplasia and in-stent stenosis in Ossabaw miniature swine. Coron Artery Dis 2008;19(1):27-31
   PubMedGoogle Scholar
• Clark AN, Youkey R, Liu X, et al. A1 adenosine receptor activation promotes angiogenesis and release of VEGF from monocytes. Circ Res 2007;101(11):1130-8
   PubMedGoogle Scholar